Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2941-2960 of 3,900 trials

Anesthesia in Newborns: Propofol vs. Thiopental

We are studying the right doses of propofol and thiopental for safely inducing anesthesia in newborns. The trial also examines how these drugs affect breathing and heart function.

Neonates Undergoing General Anesthesia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Ewing Sarcoma: Comparing Chemotherapy Treatments

We are studying different chemotherapy regimens for patients with recurrent or refractory Ewing Sarcoma. Our goal is to find the most effective and patient-friendly treatment option.

Ewing's Sarcoma3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Prostate Cancer Imaging: 99mTc-MIP-1404 SPECT/CT Study

We are comparing a new imaging technique to standard methods for detecting prostate cancer spread in patients. This study aims to see if the new method improves detection of lymph node and bone metastases.

Prostate Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesOtolaryngologyUrology

Pulmonary Tuberculosis: Cysteamine Therapy Study

We are investigating the safety of cysteamine as an additional treatment for adults with pulmonary tuberculosis. This study aims to see how it affects bacterial load and immune response during standard TB therapy.

Pulmonary Tuberculosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

CAR T Cell Therapy for Acute Leukemia in Young Patients

We are studying a new treatment using donor-derived CAR T cells for children and young adults with recurrent acute leukemia. The trial aims to assess the safety and effectiveness of this therapy after previous stem cell transplantation.

Recurrent Acute Lymphocytic Leukaemia>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Polycystic Kidney Disease: GSK4771261 Study

We are evaluating a new medication for safety and effectiveness in healthy individuals and those with autosomal dominant polycystic kidney disease. This study aims to understand how the drug works in different groups of people.

Polycystic Kidney Disease (Autosomal Dominant)1-2 yearsSafety phase (I)Internal MedicineNephrology

Preventing Relapses in Minimal Change Nephrotic Syndrome with Rituximab

We are studying whether Rituximab can help adults with Minimal Change Nephrotic Syndrome stay in remission after their first episode. This trial looks at the effectiveness and safety of the treatment over time.

Minimal Change Nephrotic Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNephrology

GRAALL2014: Clinical Trial Study

We are investigating a new treatment approach for a specific health condition. This trial aims to understand its effects and potential benefits for participants.

Acute Lymphoblastic Leukemia (ALL)>2 yearsEfficacy phase (II)Internal Medicine

Hematologic Malignancies: HTLP Injection Study

We are testing a new injection to help adults with blood cancers recover their immune system after umbilical cord blood transplantation. This study aims to see if it is safe and effective for improving recovery.

Acute Myeloid Leukemia (AML)>2 yearsSafety phase (I)Hematology

Ruxolitinib for Children with Hemophagocytic Lymphohistiocytosis

We are studying whether Ruxolitinib, combined with corticosteroids, can improve survival in children with HLH until they receive a stem cell transplant. The trial will also look at how well the treatment works and any side effects.

Haemophagocytic Lymphohistiocytosis in Children>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Oropharyngeal Cancer: Comparing Treatment Options

We are studying different treatment regimens for patients with intermediate and high-risk oropharyngeal cancer to see if they improve survival and quality of life. This trial also aims to evaluate side effects and the cost-effectiveness of these treatments.

Oropharyngeal Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

High-Risk Polycythemia Vera: Ruxolitinib vs. Standard Therapy

We are comparing a new medication, ruxolitinib, with standard treatments for high-risk polycythemia vera patients. The goal is to see which option better prevents serious complications and improves quality of life.

Polycythemia Vera>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Pediatric Hepatic Tumor Trial: Evaluating Treatments for Hepatoblastoma and Hepatocellular Carcinoma

We are studying different treatment approaches for children with liver tumors to see which may improve outcomes and reduce side effects. This trial also aims to collect samples for future research on these cancers.

Liver Cancer (Hepatoblastoma and Hepatocellular Carcinoma)≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesHepatologyOncology

Acute Myeloid Leukemia: Gemtuzumab Ozogamicin Study for Children

We are testing a new treatment combining gemtuzumab ozogamicin with standard chemotherapy for children with acute myeloid leukemia. The study aims to find the best dose and compare its effectiveness with current therapies.

Acute Myeloid LeukaemiaConfirmation phase (III)No PlaceboStandard MedicinesOncologyPediatrics

Acute Myeloid Leukemia: Venetoclax vs. Intensive Chemotherapy

We are studying whether venetoclax with low-dose cytarabine can improve outcomes for patients with favorable risk acute myeloid leukemia compared to intensive chemotherapy. This trial will help us understand the best treatment options for this condition.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Cancer Imaging: New Non-Invasive Technique

We are exploring a new imaging method that combines two techniques to study how cancer cells and healthy tissues use energy. This may help improve cancer diagnosis and treatment strategies.

Pancreatic Neuroendocrine TumorNeuroendocrine CarcinomaSoft Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementAllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryPulmonologyRheumatologyUrology

Breast Cancer Treatment: Fulvestrant with Palbociclib

We are studying whether combining fulvestrant with palbociclib helps postmenopausal women with hormone receptor-positive metastatic breast cancer live longer without disease progression compared to fulvestrant alone. This trial is for women who have completed at least five years of hormonal therapy and remained disease-free for over a year, or who have newly diagnosed metastatic disease.

Metastatic Breast Cancer1-2 yearsEfficacy phase (II)Standard MedicinesOncology

ANCA-Vasculitis: Corticosteroid Dosing Study

We are investigating if taking corticosteroids twice daily helps patients with ANCA-vasculitis maintain better blood sugar levels. This study will measure glucose control using continuous monitoring.

ANCA-associated VasculitisRapid-Progressive Glomerulonephritis≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyRheumatology

HIV-1 Infection: ART with Long-Acting Antibodies

We are studying whether adding long-acting HIV-specific antibodies to standard treatment can help people with primary HIV-1 infection achieve better control after stopping therapy. This trial will also look at how well participants tolerate the treatment.

HIV-1 Infection>2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesPartially RemoteInfectious Diseases

Immunotherapy for Cutaneous Squamous Cell Carcinoma

We are studying whether immunotherapy can help patients with skin cancer achieve remission without surgery or radiation. This trial aims to assess the treatment's effectiveness and safety over time.

Skin Cancer (Cutaneous Squamous Cell Carcinoma)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology